PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

In a pilot trial and clinical sample-based investigations, the drug Foralumab decreased inflammatory markers in patients with COVID-19

2023-03-08
(Press-News.org) In a pilot trial and clinical sample-based investigations, the drug Foralumab decreased inflammatory markers in patients with COVID-19 Similar reduction in inflammatory markers were seen when given to patients with multiple sclerosis A pilot trial by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the drug Foralumab, an anti-CD3 monoclonal antibody. Investigators found evidence that the drug dampened the inflammatory T cell response and decreased lung inflammation in patients with COVID-19. Further analysis showed the same gene expression modulation in patients with multiple sclerosis, who experienced decreased brain inflammation, suggesting that Foralumab could be used to treat other diseases. Their results are published in the Proceedings of the National Academy of Sciences.

“We discovered a way to shut down inflammation not only seen in COVID-19, but also in a patient with multiple sclerosis as well as in healthy patients,” said lead author Thais Moreira, PhD, an assistant scientist at the Ann Romney Center for Neurologic Diseases at BWH and an instructor in Neurology at Harvard Medical School. “This is very exciting because not only does our study suggest that this new monoclonal antibody drug is safe and can modulate the immune system without major side effects, but it can also decrease inflammation in multiple realms, so it may be useful for treating other diseases.”

“Inflammation is a major cause of many diseases,” said senior author Howard Weiner, MD, founder and director of the Brigham Multiple Sclerosis Center and co-director of the Ann Romney Center for Neurologic Diseases. “Our center has spent decades looking for novel ways to treat disease where there is abnormal inflammation in a way that is safe and effective.”

In both COVID-19 and multiple sclerosis, the immune system is overactive. Foralumab, manufactured by Tiziana Life Sciences, is a drug that stimulates regulatory T cells of the immune system, or anti-inflammatory cells, resulting in decreased inflammation. This contrasts with other monoclonal antibodies previously given to treat or prevent symptoms of COVID-19 (such as Evusheld) that target the SARS-CoV-2 spike protein, which only had activity against specific variants and subvariants.

In 2020, Moreira traveled to Brazil to carry out this study of Foralumab, which was given nasally to 39 patients with mild-to-moderate COVID-19 infections. Blood analysis showed signs that the patients who received 100ug of Foralumab each day for 10 days experienced less lung inflammation than their counterparts who did not. These findings led the team to carry out a sophisticated gene expression analysis to see how Foralumab was working to modulate the immune response in order to reduce inflammation. This revealed a pattern of three specific genes (NKG7, TGF beB1, and GIMAP7) involved with the anti-inflammatory effects of the drug, not only in the COVID-19 patients from the 2020 study, but also in a patient with multiple sclerosis at Brigham and Women’s Hospital and in healthy volunteers as well.

“This is the first nasal monoclonal antibody—other monoclonal antibody treatments were delivered intravenously and are no longer given as treatment because they are not effective against currently circulating viral variants,” said Weiner. “Based on our studies, we expect that Foralumab may work on all variants as it acts on immune effects. This is promising for other diseases because it works on inflammation which is a major driver of many diseases.”

Given the limitations of the small sample sizes studied, the team is moving ahead with a placebo-controlled double-blind trial in progressive multiple sclerosis as well as planning a new trial to study long COVID.

“Moreira’s discovery of a common pathway and mechanism by which Foralumab modulates the immune system gives us a biomarker that we can use to monitor treatment,” said Weiner. “Next, we are going to look at studying the use of Foralumab in long COVID, larger studies of multiple sclerosis, and other diseases such as Alzheimer's disease.”

Disclosures: H.L.W. is chair of the Scientific Advisory Board of Tiziana and received consulting fees and stock options from the company. T.C. is a member of the scientific advisory board and serves as a consultant to Tiziana Life Sciences. CMB-A serves as a consultant to Tiziana Life Sciences. T.G.M. and K.T.F.M. received consultation fees from Tiziana Life Sciences to monitor the clinical trials in which samples were used in this present work. In addition to providing Foralumab, Tiziana Life Sciences also provided financial assistance to the trial and immunological studies but did not participate in statistical analysis or data interpretation.

Funding: This study was funded by the Ann Romney Center for Neurological Diseases at Brigham and Women’s Hospital.

Paper cited: Moreira, T. et al. “Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19.” Proceedings of the National Academy of Sciences, DOI:10.1073/pnas.2220272120

END


ELSE PRESS RELEASES FROM THIS DATE:

Scientists show how gene expression controls synaptic plasticity in the aging human brain

Scientists show how gene expression controls synaptic plasticity in the aging human brain
2023-03-08
Scientific evidence shows how the cognitive decline in Alzheimer’s disease (AD) is caused by the buildup of amyloid beta proteins, which promote synaptic malfunction. One of the neuropathological features in the brains of patients with AD is the degeneration of the basal forebrain cholinergic neurons, leading to a decrease in the number of cholinergic projections to the hippocampus. As a symptomatic treatment of AD, cholinergic neurotransmission is enhanced by the use of certain drugs, known as acetylcholinesterase inhibitors. For better prevention and treatment of cognitive disorders like AD and schizophrenia, it is necessary to understand how acetylcholine regulates synaptic transmissions.   Higher ...

UTSA ScooterLab receives $1.7M NSF award to deploy a fleet of data collecting e-scooters

UTSA ScooterLab receives $1.7M NSF award to deploy a fleet of data collecting e-scooters
2023-03-08
When a speedy campus scooter nearly collided with Murtuza Jadliwala, he had an epiphany. The micro-mobility form of transportation could be a vehicle for change. Scooters carry people as well as sensors—sensors that can collect a wealth of data. This data is key to improving the quality of life. With that in mind, Jadliwala, an associate professor in the UTSA Department of Computer Science, created the ScooterLab, which has received a $1.7M grant from the National Science Foundation. “This funding is critical for ScooterLab as it enables us to take this community research infrastructure from vision to reality,” Jadliwala said. “We are hoping that our new research ...

Two-year mission to study human impact on Europe’s seas and coastal regions

Two-year mission to study human impact on Europe’s seas and coastal regions
2023-03-08
Europe’s coastlines are environments rich in biodiversity that also represent important sites of  industry, culture, and heritage. Forty per cent of Europe’s population live within a coastal region, and many European societies have been, and still are, defined by their relationships with the sea.   Our seas and coasts represent key ecosystems that host an extremely rich diversity of life and play critical roles in the stability and sustainability of wider ecosystems. However, anthropogenic interferences such as pollution, farming, and building ...

Do school shootings increase stress-related emergency department visits in local communities?

2023-03-08
New research in Contemporary Economic Policy reveals that school shootings may worsen mental health in surrounding communities and increase health system costs. For the study, investigators compared the number of stress-related emergency department visits by California residents in zip-codes within 5 miles of school shootings and by California residents in zip-codes 10–15 miles from school shootings, both before and after these violent events. Compared with before school shootings, exposure to school shootings and to fatal school shootings was associated with increases of 0.7 and 1.5 ...

Blocking gene that inhibits root growth may enhance drought resistance in crops

2023-03-08
A strong root system allows crops to absorb water and nutrients from the soil, but scientists have little information about the genes that control root development. Recent research published in New Phytologist reveals that blocking a negative regulator gene of root development leads to enhanced root growth in plants. The gene, called RRS1 (Robust Root System 1), encodes an R2R3-type MYB family transcription factor that activates the expression of another gene (OsIAA3) that inhibits root growth. Knocking out RRS1 in plants led to longer root length, longer lateral root length, and larger lateral root density. Also, a natural variant of RRS1 ...

Could having an irregular heart rhythm affect a person’s risk of developing dementia?

2023-03-08
In a large study of diverse adults in California, individuals with newly diagnosed atrial fibrillation, or an irregular heart rhythm, had a modestly elevated risk of developing dementia. The Journal of the American Heart Association study found that this risk was higher in younger adults and those without chronic kidney disease, but did not substantially vary across sex, race, or ethnicity. In the study of nearly 200,000 adults, incidence rates for dementia over a median follow-up of 3.3 years were 2.79 versus 2.04 per ...

Can virtual reality tools help teach obstetrics and gynecology topics to medical students?

2023-03-08
Results from a trial published in the International Journal of Gynecology & Obstetrics support the benefit of 3D virtual reality lessons to improve medical students’ knowledge and understanding of complex topics in obstetrics and gynecology. For the study, 21 students took part in a 15-minute virtual reality learning environment (VRLE) experience on the stages of fetal development, and 20 students received a PowerPoint tutorial on the same topic. Knowledge increased after both learning experiences, but it was only retained in the VRLE group at one-week follow up. Questionnaires completed by participants reflected a high ...

Models predict nursing home residents’ risk of fall-related injuries

2023-03-08
In research published in the Journal of the American Geriatrics Society, investigators developed and validated models that can predict the risk of fall-related injuries in nursing home residents based on routinely collected clinical data. The prediction models achieved good discrimination and excellent calibration for accurately estimating individuals’ six-month and two-year risk of fall-related injuries. One short model that performed well included only five predictors: Activities of Daily Living Score, recent fall, hospitalization in the previous year, ability to walk in room, and history of non-hip fractures. “These models ...

Protein derived from bone may help combat osteosarcoma

2023-03-08
A study published in the Journal of Orthopaedic Research has identified a bone matrix protein called Secreted phosphoprotein 24 kD (Spp24) that may help to treat osteosarcoma, the most common type of bone cancer. In experiments conducted in cells and mice, investigators found that Spp24 inhibits the proliferation and invasiveness of osteosarcoma tumor cells and promotes their apoptosis, or death. Mechanistically, Spp24 binds to and neutralizes a protein called bone morphogenetic protein 2, which has tumor enhancing properties. “Spp24 and ...

THE LANCET: Contracting a respiratory infection in early childhood associated with a higher risk of dying from respiratory disease as an adult, study finds

2023-03-08
Peer-reviewed / Observational study / People Study of 3,589 people over 73 years suggests that children who had a lower respiratory tract infection (LRTI), such as bronchitis or pneumonia, by the age of two were almost twice as likely to die prematurely in adulthood from respiratory diseases, independent of socioeconomic factors and smoking status. After adjusting for cofounders, analysis suggests a 2.1% rate of premature adult death from respiratory disease among those who had a LRTI in early childhood, compared to 1.1% among those who did not report a LRTI before the age of ...

LAST 30 PRESS RELEASES:

Resistance training may improve nerve health, slow aging process, study shows

Common and inexpensive medicine halves the risk of recurrence in patients with colorectal cancer

SwRI-built instruments to monitor, provide advanced warning of space weather events

Breakthrough advances sodium-based battery design

New targeted radiation therapy shows near-complete response in rare sarcoma patients

Does physical frailty contribute to dementia?

Soccer headers and brain health: Study finds changes within folds of the brain

Decoding plants’ language of light

UNC Greensboro study finds ticks carrying Lyme disease moving into western NC

New implant restores blood pressure balance after spinal cord injury

New York City's medical specialist advantage may be an illusion, new NYU Tandon research shows

Could a local anesthetic that doesn’t impair motor function be within reach?

1 in 8 Italian cetacean strandings show evidence of fishery interactions, with bottlenose and striped dolphins most commonly affected, according to analysis across four decades of data and more than 5

In the wild, chimpanzees likely ingest the equivalent of several alcoholic drinks every day

Warming of 2°C intensifies Arctic carbon sink but weakens Alpine sink, study finds

Bronze and Iron Age cultures in the Middle East were committed to wine production

Indian adolescents are mostly starting their periods at an earlier age than 25 years ago

Temporary medical centers in Gaza known as "Medical Points" (MPs) treat an average of 117 people daily with only about 7 staff per MP

Rates of alcohol-induced deaths among the general population nearly doubled from 1999 to 2024

PLOS One study: In adolescent lab animals exposed to cocaine, High-Intensity Interval Training boosts aversion to the drug

Scientists identify four ways our bodies respond to COVID-19 vaccines

Stronger together: A new fusion protein boosts cancer immunotherapy

Hidden brain waves as triggers for post-seizure wandering

Music training can help the brain focus

Researcher develop the first hydride ion prototype battery

MIT researchers find a more precise way to edit the genome

‘Teen’ pachycephalosaur butts into fossil record

Study finds cocoa extract supplement reduced key marker of inflammation and aging

Obesity treatment with bariatric surgery vs GLP-1 receptor agonists

Nicotinamide for skin cancer chemoprevention

[Press-News.org] First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases
In a pilot trial and clinical sample-based investigations, the drug Foralumab decreased inflammatory markers in patients with COVID-19